Back to Agenda
SESSION 5: REGULATORY PRACTICES ADDRESSING SCIENTIFIC AND THERAPEUTIC INNOVATION
Session Chair(s)
Inas Chehimi
Head Regulatory Affairs - Middle East & North Africa, Novartis Pharma Services AG, United Arab Emirates
Reviewing some of the paradigm shifts in technical research and development; “How changes in the scientific understanding of disease are influencing changes in regulatory pathways”.
Speaker(s)
Trevor M. Jones, CBE
former Director General ABPI, King's College London, United Kingdom
Introduction
Balazs Sarkadi
Head of Biomembrane Research Group, Hungarian Academy of Sciences, Research Centre For Natrual Sciences, Hungary
Regulatory Pathway / Share Experience
Ramy Behbehani, MS
Drug Registration and Release Superintendent, Kuwait Drug & Food Control Adminstration Kuwait, Kuwait
Mikkel Oestergaard, PHD
Epidemiologist, Roche Products Limited, Switzerland
Industry R&D Overview / FDA Regulatory Pathways and EU Industry
Have an account?